EMEA
Janssen: why transparency is essential to the health of our industry
August 29, 2014Medical Communications, Research and Development, Sales and Marketing EFPIA, EMEA, Goldacre, Janssen, alltrials, transparency
The pharmaceutical industry is moving forward, working together to ensure patients have access to new and innovative medicines.However, more must …
Eisai expands UK base
March 21, 2012Sales and Marketing EMEA, Eisai, Hatfield, expansion
Eisai is expanding its UK headquarters to support the company’s growing European, Middle Eastern and African business. The expansion will …
EMA readies paediatric trials network
May 14, 2010Research and Development EMA, EMEA, paediatric, paediatric trials
The European Medicines Agency is about to press the start button on its long-planned network for clinical studies in children. …
In brief: European Medicines Agency news
January 26, 2010Research and Development, Sales and Marketing Arepanrix, Arzerra, EMEA, GSK, Tysabri
GlaxoSmithKline’s influenza vaccine Arepanrix has been granted conditional marketing authorisation in Europe under an emergency fast-track procedure.It is the fourth …
Patient involvement must improve, says European regulator
December 31, 2009Sales and Marketing EMEA, patients
The European Medicines Agency (EMEA) has admitted that the level of patient involvement in its activities is unsatisfactory.As a result …
EMA: Aligning regulation with the lifecycle of medicines
November 30, 2009Research and Development EMA, EMEA, Thomas Lönngren, regulatory affairs
The European Agency for the Evaluation of Medicinal Products was set up in 1995 in London’s Docklands, an isolated eastern …
Merck Serono asks EMEA to re-think Erbitux rejection
July 30, 2009Research and Development, Sales and Marketing Cancer, EMEA, Erbitux, Europe, Merck Serono
Merck Serono is to appeal against the European rejection of Erbitux as a lung cancer treatment.Erbitux has been rejected as …
Onglyza and Cimzia recommended by CHMP
July 2, 2009Research and Development, Sales and Marketing AZ, BMS, EMEA, Europe, Ongylza
Bristol-Myers Squibb andAstraZeneca's type II diabetes treatment Onglyza is among the brands to have received positive opinions from the Committee …
Lonngren lashes out at late warning
November 1, 2004EMA, EMEA, Lonngren, Vioxx
Thomas Lonngren, the head of Europe’s medicines regulator the EMEA has spoken out about Merck’s withdrawal of Vioxx, saying the …
